IMR Press / EJGO / Volume 25 / Issue 1 / pii/2004119

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Clinical features of familial ovarian cancer lacking mutations in BRCAI or BRCA2

Show Less
1 Clinic of Surgical Gynecology and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Szczecin (Poland)
2 Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin (Poland)
3 Department of Chemotherapy, Regional Oncology Hospital, Szczecin (Poland)
4 Clinics of Rheumatology, Pomeranian Medical University, Szczecin (Poland)
5 Centre for Research in Womens Health, Sunnybrook and Womens’ College Health Sciences Center, University of Toronto, Toronto, Ontario (Canada)
Eur. J. Gynaecol. Oncol. 2004, 25(1), 99–100;
Published: 10 February 2004

Purpose of investigation: The purpose of the present study was to identify the clinical and pathologic features of ovarian cancers in patients who have a family history of breast or ovarian cancer but who do not have a mutation in the BRCA1 or BRCA2 gene. Methods: 303 patients with ovarian cancer were reviewed for clinical features and for cancer family histories. After the exclusion of 51 patients known to carry BRCA1 or BRCA2 mutations, 24 patients with familial cancer were compared with 228 patients with non-familial cancer. Results: Patients with familial cancer were more likely to have grade 2 tumors, Stage II disease and to present between ages 51 and 60 than were non-familial controls. Ten of 24 patients in the familial group presented between ages 51 and 60 with a grade 2 tumor compared to 3.0 expected (p = 0.001). Conclusions: Families of women who present with grade 2 ovarian cancer between the ages of 51 and 60 may have an unidentified ovarian cancer susceptibility gene.

Hereditary ovarian cancer
Back to top